Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5581753 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 15 Pages |
Abstract
AlloHCT2 remains a potential curative option in a subset of patients with relapsed ALL after the first AlloHCT.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Monzr M. Al Malki, Ibrahim Aldoss, Tracey Stiller, Ryotaro Nakamura, David S. Snyder, Stephen J. Forman, Vinod Pullarkat,